3 Outperforming IPO Stocks Flying Under The Radar

Analysts expect IMAB’s revenues to increase in the current year to $204.92 million.

IMAB’s POWR Ratings reflect this promising outlook. It has a “Buy” rating with an “A” for Industry Rank, and a “B” for Trade Grade, Buy & Hold Grade, and Peer Grade. It is currently ranked #39 of 240 stocks in the Medical – Pharmaceuticals industry.

Schrodinger, Inc. (SDGR - Get Rating)

SDGR designs computational software platforms for biopharmaceutical and industrial companies worldwide. It operates in two segments – software and drug discovery and has a portfolio of wholly-owned programs. SDGR began trading on the NASDAQ Global Select exchange on February 6. The company raised approximately $202 million through an initial public offering of $11.88 million shares, priced at $17 per share.

SDGR gained 84.7% on its first day of trading and gained more than 225% within 5 months to hit its all-time high of $99.50 in July, and 188.8% to date.

SDGR’s total revenue increased 29% year-over-year to $25.80 million in the third quarter ended September 30, 2020. This can be attributed to a 42% rise in software revenues. Gross profit rose 43% from the year-ago value to $15.30 million, while net income increased substantially from the negative values reported in the same period last year to $3.90 million. Moreover, SDGR has raised an additional $325.60 million through a follow-on offering over this period.

On November 23, SDGR entered a multi-year discovery collaboration with Bristol Meyers Squibb Company to develop and commercialize advanced molecule therapeutics. SDGR received $55 million in upfront payments through this partnership and is eligible to receive up to $2.70 billion for preclinical, development, and sales-based milestone payments.

The consensus EPS estimate of $0.04 for the next year indicates a 113.8% improvement year-over-year. The consensus revenue estimate of $173.50 million for 2021 indicates a 54.5% rise from the year-ago value.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.